CONGENITAL HYPERINSULINISM TREATMENT MARKET ANALYSIS

Congenital Hyperinsulinism Treatment Market, by Disease Type (KATP-HI, GDH-HI, GK-HI, Other (SCHAD HI,HNF4A/HNF1A, etc.)), by Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other (Sirolimus, Chlorothiazide, etc.), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5329
Pages :190
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Congenital Hyperinsulinism Treatment Market: Key Players

Major players operating in the global congenital hyperinsulinism treatment market include Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.